Graphene Quantum Dot-Gadolinium Chelate MRI Contrast Agent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gadolinium-based MRI contrast agents have high gadolinium content, leading to cytotoxicity and biological safety issues, while also having inferior T1-weighted contrast effects.
Innovation Solution
A graphene quantum dots-gadolinium ion chelate with hydrophilic groups on its surface is developed, which is synthesized using a method involving the preparation of graphene oxide, oxidation, and chelation with Gd3+, resulting in a nanomaterial with excellent biocompatibility and low cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gadolinium-based contrast agents are used to improve MRI imaging quality, then the imaging quality is improved, but the gadolinium content is high leading to cytotoxicity and biological safety problems
Solution Approach 1:
The patent uses graphene quantum dots as a carrier material to chelate gadolinium ions, forming a composite contrast agent. The graphene quantum dots provide a stable platform that allows significant reduction of gadolinium content while maintaining imaging performance, thereby reducing cytotoxicity. The composite structure enables the gadolinium to be delivered efficiently without requiring high concentrations that would cause toxicity.
Solution Approach 2:
The patent changes the concentration parameter of gadolinium from high levels in traditional agents to extremely low levels in the graphene quantum dot-based agent. By optimizing the chelation ratio and utilizing the high efficiency of the graphene carrier, the agent achieves effective contrast enhancement with minimal gadolinium content, resolving the toxicity issue while preserving imaging quality.
2Measurement precision
If gadolinium-based contrast agents are used to enhance T1-weighted contrast effect, then the contrast effect is improved, but the gadolinium dosage is high causing biological safety issues
Solution Approach 1:
The graphene quantum dots-gadolinium ion chelate composite enables highly efficient T1-weighted contrast effect with extremely low gadolinium dosage. The graphene quantum dots act as a highly effective carrier that amplifies the contrast effect per unit of gadolinium, allowing the patent to achieve superior T1-weighted imaging with minimal gadolinium content, thus resolving the contradiction between contrast effect and dosage.
3Object-affected harmful factors
If chelating ligands are used to inhibit cytotoxicity of Gd3+, then the cytotoxicity is reduced, but the gadolinium content and actual dosage remain substantially high
Solution Approach 1:
The patent employs graphene quantum dots as a novel chelating carrier that fundamentally changes the approach to reducing cytotoxicity. Instead of relying on traditional ligands that require high gadolinium content to achieve safety, the graphene quantum dots provide a stable, low-dosage platform that inherently reduces toxicity while minimizing gadolinium content through efficient chelation and carrier-mediated delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The graphene quantum dots-gadolinium ion chelate exhibits a high relaxation rate r1 of 72 mM−1s−1, significantly surpassing commercial T1-weighted contrast agents, while requiring a much lower gadolinium dosage, thus minimizing cytotoxicity and enhancing imaging quality.
Implementation Method 1
various ligands are usually used to chelate with Gd3+ to minimize free Gd3+ leakage
Implementation Method 2
GQDs not only have the excellent properties of graphene, such as large specific surface area, high electron mobility and good mechanical strength, but also have the good properties of excellent fluorescence property and photostability
Implementation Method 3
Gadolinium ion (Gd3+) can provide seven unpaired electrons, resulting in a higher longitudinal relaxation rate (r1)
Data Source
AI summary
A graphene quantum dots-gadolinium ion chelate (Gd@GQDs) nanomaterial with hydrophilic groups on the surface has a preparation method that includes: preparing graphene oxide by using a Hummers method; subsequently, subjecting the graphene oxide to heating, oxidation, and purification to obtain pure graphene quantum dots; and finally, chelating the graphene quantum dots with Gd3+ to form stable Gd@GQDs. The Gd@GQDs is easily dispersed in water, phosphate buffered solution (PBS), biological medium and other aqueous system, has good biocompatibility and low cytotoxicity, shows an excellent T1-weighted contrast performance in a 1.5-Tesla magnetic resonance testing system, and has a relaxation rate r1 as high as 72 mM−1s−1, the value of r1 being 20 times higher than that of the current commercial T1-weighted magnetic resonance imaging contrast agent Gd-DTPA.